Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9790MR)

This product GTTS-WQ9790MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9790MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ38MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ1759MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ13567MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ9306MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ14341MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ13153MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ15714MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ12924MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW